[Edaily Reporter Kim Seung-kwon ] KB Asset Management has secured a stake of more than 5% in medical artificial intelligence (AI) specialist JLK, Inc.(322510), becoming its second-largest shareholder.

According to the Financial Supervisory Service’s electronic disclosure system (DART) on the 22nd, KB Asset Management acquired 1,309,845 new shares of JLK, Inc., securing a 5.09% stake.

JLK, Inc. recently laid the groundwork for non-insured use in domestic medical settings after its stroke AI solution, “JLK-CTP,” was designated for a deferral of the New Medical Technology Evaluation. The company is currently carrying out a national R&D project to expand global clinical trials and regulatory approvals.

The company recently completed the development of “TRACEGENT,” an AI platform for medical imaging in Alzheimer’s disease, and is currently developing “JOOMED,” a multimodal large language model (LLM) platform specialized for medical imaging.

It is also accelerating its expansion into overseas markets. In the United States, the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) are pushing to introduce the “RAPID” program, which links the approval of innovative medical devices with insurance coverage procedures, raising expectations for an improved commercialization environment for medical AI companies.

JLK, Inc. is pursuing entry into the U.S. market based on FDA approval and securing insurance reimbursement rates, and plans to expand its global business through this initiative.

A JLK, Inc. official stated, “The medical AI market is entering a phase where actual commercialization capabilities are more important than technological competition,” adding, “Based on our domestic commercialization achievements, we plan to accelerate our expansion into global markets, including the U.S.”